ofatumumab
ofatumumab is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including KESIMPTA. Available dosage forms: injection, solution, liquid.
Drug Details
- Generic Name
- ofatumumab
- Brand Names
- KESIMPTA
- Application Number
- BLA125326
- Sponsor
- Novartis Pharmaceuticals Corporation
- NDC Codes
- 2
- Dosage Forms
- INJECTION, SOLUTION, LIQUID
- Routes
- SUBCUTANEOUS
- Active Ingredients
- OFATUMUMAB
Indications and Usage
1 INDICATIONS AND USAGE KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )